206 related articles for article (PubMed ID: 36541357)
21. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
[TBL] [Abstract][Full Text] [Related]
22. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy.
Jung SC; Park ES; Choi EN; Kim CH; Kim SJ; Jin DK
Mol Cells; 2010 Jul; 30(1):13-8. PubMed ID: 20652491
[TBL] [Abstract][Full Text] [Related]
24. Differences in MPS I and MPS II Disease Manifestations.
Hampe CS; Yund BD; Orchard PJ; Lund TC; Wesley J; McIvor RS
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360653
[TBL] [Abstract][Full Text] [Related]
25. Identification and characterization of 20 novel pathogenic variants in 60 unrelated Indian patients with mucopolysaccharidoses type I and type II.
Uttarilli A; Ranganath P; Matta D; Md Nurul Jain J; Prasad K; Babu AS; Girisha KM; Verma IC; Phadke SR; Mandal K; Puri RD; Aggarwal S; Danda S; Sankar VH; Kapoor S; Bhat M; Gowrishankar K; Hasan AQ; Nair M; Nampoothiri S; Dalal A
Clin Genet; 2016 Dec; 90(6):496-508. PubMed ID: 27146977
[TBL] [Abstract][Full Text] [Related]
26. High-dose enzyme replacement therapy in murine Hurler syndrome.
Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
[TBL] [Abstract][Full Text] [Related]
27. A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation.
Mashima R; Ohira M; Okuyama T; Onodera M; Takada S
Sci Rep; 2023 May; 13(1):7865. PubMed ID: 37188686
[TBL] [Abstract][Full Text] [Related]
28. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
[TBL] [Abstract][Full Text] [Related]
29. Non-invasive intravenous administration of AAV9 transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome.
Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Singh SM; Smith MC; Belur LR; Low WC; Kozarsky KF; McIvor RS
Mol Genet Metab Rep; 2023 Mar; 34():100956. PubMed ID: 36704405
[TBL] [Abstract][Full Text] [Related]
30. Generation and characterization of an immunodeficient mouse model of mucopolysaccharidosis type II.
Smith MC; Belur LR; Karlen AD; Podetz-Pedersen K; Erlanson O; Laoharawee K; Furcich J; Lund TC; You Y; Seelig D; Webber BR; McIvor RS
Mol Genet Metab; 2023 Apr; 138(4):107539. PubMed ID: 37023503
[TBL] [Abstract][Full Text] [Related]
31. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
[TBL] [Abstract][Full Text] [Related]
32. Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.
Schuh RS; Gonzalez EA; Tavares AMV; Seolin BG; Elias LS; Vera LNP; Kubaski F; Poletto E; Giugliani R; Teixeira HF; Matte U; Baldo G
Gene Ther; 2020 Feb; 27(1-2):74-84. PubMed ID: 31827259
[TBL] [Abstract][Full Text] [Related]
33. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome.
Wang D; Zhang W; Kalfa TA; Grabowski G; Davies S; Malik P; Pan D
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19958-63. PubMed ID: 19903883
[TBL] [Abstract][Full Text] [Related]
34. Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation.
Lee JH; Choe YH; Kim SJ; Paik KH; Jin DK
Yonsei Med J; 2011 Mar; 52(2):263-7. PubMed ID: 21319344
[TBL] [Abstract][Full Text] [Related]
35. Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.
Nan H; Park C; Maeng S
Biomed Res Int; 2020; 2020():2408402. PubMed ID: 33344633
[No Abstract] [Full Text] [Related]
36. Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.
Hinderer C; Bell P; Louboutin JP; Zhu Y; Yu H; Lin G; Choa R; Gurda BL; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Tarantal AF; Casal ML; Haskins ME; Wilson JM
Mol Ther; 2015 Aug; 23(8):1298-1307. PubMed ID: 26022732
[TBL] [Abstract][Full Text] [Related]
37. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.
Ou L; Przybilla MJ; Koniar B; Whitley CB
Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892
[TBL] [Abstract][Full Text] [Related]
38. Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits.
Baldo G; Wozniak DF; Ohlemiller KK; Zhang Y; Giugliani R; Ponder KP
J Inherit Metab Dis; 2013 May; 36(3):499-512. PubMed ID: 22983812
[TBL] [Abstract][Full Text] [Related]
39. Intravenous delivery for treatment of mucopolysaccharidosis type I: A comparison of AAV serotypes 9 and rh10.
Belur LR; Podetz-Pedersen KM; Tran TA; Mesick JA; Singh NM; Riedl M; Vulchanova L; Kozarsky KF; McIvor RS
Mol Genet Metab Rep; 2020 Sep; 24():100604. PubMed ID: 32461912
[TBL] [Abstract][Full Text] [Related]
40. The natural history of neurocognition in MPS disorders: A review.
Shapiro EG; Eisengart JB
Mol Genet Metab; 2021 May; 133(1):8-34. PubMed ID: 33741271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
